ESMO 2017 | The importance of biomarkers in treating melanoma patients

With the vast range of options now available to treat melanoma, it is important that we identify biomarkers which can help us to determine the most suitable treatment for each patient. Christian Blank, MD, PhD, from the Netherlands Cancer Institute, Amsterdam, Netherlands talks to us about his presentation on the topic of biomarkers, and discusses where future work in this field should focus. This presentation was recorded at the 2017 European Society for Medical Oncology (ESMO) held in Madrid, Spain.